[go: up one dir, main page]

DE60121794D1 - Verwendung von pyridoxamin für die behandlung und unterdrückung von komplikationen im zusammenhang mit adipositas - Google Patents

Verwendung von pyridoxamin für die behandlung und unterdrückung von komplikationen im zusammenhang mit adipositas

Info

Publication number
DE60121794D1
DE60121794D1 DE60121794T DE60121794T DE60121794D1 DE 60121794 D1 DE60121794 D1 DE 60121794D1 DE 60121794 T DE60121794 T DE 60121794T DE 60121794 T DE60121794 T DE 60121794T DE 60121794 D1 DE60121794 D1 DE 60121794D1
Authority
DE
Germany
Prior art keywords
pyridoxamine
adipositas
suppression
treatment
product formation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60121794T
Other languages
English (en)
Inventor
John Baynes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Carolina
Original Assignee
University of South Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Carolina filed Critical University of South Carolina
Application granted granted Critical
Publication of DE60121794D1 publication Critical patent/DE60121794D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • External Artificial Organs (AREA)
DE60121794T 2000-11-02 2001-11-02 Verwendung von pyridoxamin für die behandlung und unterdrückung von komplikationen im zusammenhang mit adipositas Expired - Lifetime DE60121794D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24563000P 2000-11-02 2000-11-02
US31578901P 2001-08-29 2001-08-29
PCT/US2001/045415 WO2002036109A2 (en) 2000-11-02 2001-11-02 Use of pyridoxamine for the treatment and inhibition of obesity-related complications

Publications (1)

Publication Number Publication Date
DE60121794D1 true DE60121794D1 (de) 2006-09-07

Family

ID=26937355

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60121794T Expired - Lifetime DE60121794D1 (de) 2000-11-02 2001-11-02 Verwendung von pyridoxamin für die behandlung und unterdrückung von komplikationen im zusammenhang mit adipositas

Country Status (6)

Country Link
US (1) US20020128295A1 (de)
EP (1) EP1341532B1 (de)
AT (1) ATE333868T1 (de)
AU (1) AU2002218002A1 (de)
DE (1) DE60121794D1 (de)
WO (1) WO2002036109A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030146B2 (en) * 1996-09-10 2006-04-18 University Of South Carolina Methods for treating diabetic neuropathy
CA2383252A1 (en) 1999-08-24 2001-03-01 Medicure International Inc. Treatment of cardiovascular related pathologies
US7442689B2 (en) 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
ATE526023T1 (de) * 2003-06-20 2011-10-15 Nephrogenex Inc Pyridoxamin zur verwendung in der behandlung von diabetischer nephropathie bei typ ii diabetes
US20090082407A1 (en) * 2004-06-18 2009-03-26 Biostratum, Inc. Pyridoxamine for the Treatment of Diabetic Kidney Disease
US7214799B2 (en) * 2004-02-09 2007-05-08 Biostratum, Inc. Methods for the synthesis of pyridoxamine
CN100558359C (zh) * 2004-09-06 2009-11-11 兴和株式会社 肾小球病治疗剂
DE102004050353A1 (de) * 2004-10-15 2006-04-20 Basf Ag Verwendung stabiler Ammoniumsalze der Liponsäure zur Behandlung diabetischer und weiterer Störungen
CN103796648B (zh) * 2011-07-12 2019-10-25 范德比尔特大学 用γ-醛酮清除剂治疗炎症和高血压的方法
WO2018201074A1 (en) * 2017-04-27 2018-11-01 Vanderbilt University Methods for treating atherosclerosis with gamma-ketoaldehyde scavengers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288716A (en) * 1987-02-18 1994-02-22 Ulrich Speck Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis
US6228858B1 (en) * 1995-09-12 2001-05-08 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
WO2000021516A2 (en) * 1998-10-14 2000-04-20 Kansas University Medical Center Research Institute, Inc. Methods for inhibiting diabetic complications
CA2347117C (en) * 1998-10-22 2006-01-24 University Of South Carolina Methods for inhibiting diabetic complications

Also Published As

Publication number Publication date
WO2002036109A3 (en) 2003-05-30
ATE333868T1 (de) 2006-08-15
EP1341532B1 (de) 2006-07-26
EP1341532A2 (de) 2003-09-10
AU2002218002A1 (en) 2002-05-15
WO2002036109A2 (en) 2002-05-10
US20020128295A1 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
DE60121794D1 (de) Verwendung von pyridoxamin für die behandlung und unterdrückung von komplikationen im zusammenhang mit adipositas
WO2005047244A3 (en) Inhibition of fgfr3 and treatment of multiple myeloma
DE60042172D1 (de) Verfahren und zusammensetzungen zur vorbeugung oder behandlung von atherosclerose, restenose und zusammenhängenden erkrankungen
UA49869C2 (uk) Нафтил-заміщені похідні бензимідазолу, фармацевтична композиція, спосіб лікування (варіанти) та спосіб інгібування людського фактора
TW200512016A (en) Drug-coated stents and methods of use therefor
FI964789A0 (fi) Elastaasin pefluorialkyyliketoni-inhibiittoreita ja menetelmiä niiden valmistamiseksi
DE69924641D1 (de) Behandlung von asthma anhand von mek-inhibitoren
DE69317578D1 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
ATE222488T1 (de) Verwendung von anti-vegf-mitteln zur behandlung der endometriose
ATE177421T1 (de) Wasserlösliches nimesulid-salz, sowie dessen verwendung zur behandlung von entzündungen
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
ATE400301T1 (de) Arteriovenöse und venöse transplantatbehandlungen: methoden und zusammensetzungen
NO974118L (no) Trisubstituerte fenylderivater
ATE289808T1 (de) Caroteinoid-nicotinamid-zink zusammensetzungen und verfahren zur behandlung unter verwendung derselben
ATE309795T1 (de) Acetylcholinesteraseinhibitoren zur behandlung und diagnose von atemstörungen während des schlafes
DE69713620D1 (de) Verwendung von arachidonsäure und/oder docohexaensäure zur herstellung eines arzneimittels zur behandlung von dyspraxia
DE69902523D1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
ATE273708T1 (de) Wirkstoff zur prophylaxis und behandlung von krankheiten durch thromboxane a2 vermittelt
BR9709781A (pt) N-sulfonilimidazóis como fungicidas
ATE193206T1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
DE60019591D1 (de) Behandlung oder hemmung von koronarimplantat vasospasm
DE60330857D1 (de) 5-ht4 antagonisten zur behandlung von herzversagen
ATE385792T1 (de) Verwendung von derivaten von c2-substituierten indan-1-ol-systemen zur herstellung von medikamenten zur prophylaxe oder behandlung von obesitas

Legal Events

Date Code Title Description
8332 No legal effect for de